1
|
Shen CC, Cheng WY, Lee CH, Dai XJ, Chiao MT, Liang YJ, Hsieh WY, Mao TF, Lin GS, Chen SR, Liu BS, Chen JP. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer 2020; 20:709. [PMID: 32727419 PMCID: PMC7391574 DOI: 10.1186/s12885-020-07210-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Accepted: 07/23/2020] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND It has previously been shown that bevacizumab, when added to chemotherapy, improved overall survival in several cancers. In glioblastoma multiforme (GBM), bevacizumab increased progression-free survival and it is widely used for tumor recurrence, though it has failed to improve overall survival (OS) in controlled trials. However, an effective biomarker for predicting the prognosis of bevacizumab treatment has yet to be identified. This study, therefore, aimed to retrospectively analyze the polymorphisms of p53 codon 72 and the clinical characteristics of GBM specimens from Taiwanese patients. METHODS The polymorphisms of p53 codon 72 in 99 patients with GBM treated at Taichung Veterans General Hospital in Taiwan from 2007 to 2017 were analyzed using direct DNA sequencing and PCR-RFLP analysis. RESULTS We found that among these GBM patients, the distribution of codon 72 polymorphisms was 28.3% for proline homozygotes (Pro/Pro), 38.4% for arginine homozygotes (Arg/Arg), and 33.3% for proline/arginine heterozygotes (Pro/Arg). Although the polymorphisms of p53 codon 72 were not directly associated with the overall survival of GBM, both the Arg/Arg and Arg/Pro genotypes were associated with significant benefits in terms of overall survival in patients treated with CCRT plus bevacizumab compared to patients treated with CCRT alone. CONCLUSIONS This pilot study suggests that both the Arg/Arg and Arg/Pro genotypes of p53 codon 72 polymorphism may have value as independent prognostic or predictive parameters for bevacizumab treatment response and failure. Relatedly, the results of the study further demonstrate the utility of stratifying GBM patients according to bevacizumab sensitivity.
Collapse
Affiliation(s)
- Chiung-Chyi Shen
- Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan. .,Department of Physical Therapy, Hung Kuang University, No. 1650, Taiwan Boulevard Sec. 4 Taichung 407, Taichung, 43302, Taiwan. .,Department of Medicine, National Defense Medical Center, Taipei, Taiwan. .,Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. .,Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. .,Basic Medical Education, Central Taiwan University of Science and Technology, Taichung, Taiwan.
| | - Wen-Yu Cheng
- Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan.,Department of Physical Therapy, Hung Kuang University, No. 1650, Taiwan Boulevard Sec. 4 Taichung 407, Taichung, 43302, Taiwan.,Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan
| | - Chung-Hsin Lee
- Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan.,Department of Neurosurgery, Neurological Institute, Taichung Tzu Chi Hospital, Taichung city, Taiwan
| | - Xue-Jun Dai
- Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou city, China
| | - Ming-Tsang Chiao
- Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan
| | - Yea-Jiuen Liang
- Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan
| | - Wan-Yu Hsieh
- Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan
| | - Tsuo-Fei Mao
- Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan
| | - Guo-Shi Lin
- Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou city, China
| | - Shou-Ren Chen
- Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou city, China
| | - Bai-Shuan Liu
- Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan
| | - Jun-Peng Chen
- Biostatistics Task Force, Taichung Veterans General Hospital, Taichung, Taiwan
| |
Collapse
|